Integrating Teams After M&A or Strategic Partnerships

In life sciences, mergers, carve‑outs and strategic alliances are now core to how pipelines advance and products reach patients. But while the deal thesis is usually about science, assets and markets, value is delivered (or destroyed) by what happens with people and ways of working in the first 12–18 months.
This year has seen so many significant acquisition, across biotech and medtech, a few of the most memorable for me.
BioMarin → Amicus Therapeutics: approximately $4.8 billion, expanding BioMarin’s rare-disease portfolio, including Fabry and Pompe disease treatments.
Ariceum Therapeutics → Theragnostics: an acquisition centered on radiopharmaceuticals and radiolabeled PARP inhibitors; financial terms were not disclosed.
Merck KGaA → Silence Therapeutics: approximately $1.3 billion, adding an siRNA-based drug-development platform
Waters → BD’s biosciences and diagnostic-solutions business: $17.5 billion, one of the year’s largest life-sciences deals. Medtronic → CathWorks: $585 million, expanding its cardiovascular and coronary-diagnostics business.
Stryker → Amplitude Vascular Systems: $435 million upfront, plus up to $400 million in milestones, for intravascular lithotripsy technology
For CEOs, HR Directors and Talent Acquisition leaders, integration is no longer a back‑office task. It’s a strategic capability.
The unique integration challenge in life sciences
Life sciences integrations are different from many other industries because:
Critical knowledge is highly concentrated. A small group of scientists, regulatory leads or site heads often holds the history behind key decisions, filings and relationships.
Timelines are unforgiving. Clinical milestones, inspections and launches rarely pause because two companies are combining.
Partnership models are complex. Co‑development, co‑commercialisation and joint ventures mean leaders must operate in blurred organisational and governance lines.
If these realities are not addressed early, you see:
Loss of key talent just when you need them most
Delays or quality issues in ongoing trials and manufacturing
Confusion over “who decides what” across partners
Erosion of trust—internally and between alliance partners, regulators and investors
Leadership and HR: reducing disruption from day one
Get clear on the “people thesis” of the deal
Alongside the scientific and financial rationale, the top team should be able to answer:
Which teams and roles are absolutely critical to protect value (e.g., principal investigators, regulatory leads on key filings, site heads, QA/QC leaders, alliance managers)?
Where do we need speed of integration, and where do we need stability and minimal change?
What cultural differences will help or hinder us?
HR should insist this “people thesis” is explicit before integration starts. It guides every downstream decision.
Stabilise critical talent early
For high‑impact individuals and teams:
Identify them explicitly. Don’t rely on line managers alone; triangulate with programme, regulatory and quality leads.
Communicate early and directly. Senior leaders should speak with them personally about the future, not just via generic town halls.
Use tailored retention strategies. This may include retention bonuses, accelerated development opportunities, clarity on future roles, or involvement in integration design.
The message should be: “You are central to why this deal was done—and to its success.”
Align on non‑negotiables, flex on everything else
Leadership should define a small set of non‑negotiables (e.g., safety, quality, ethics, key governance rules) and be prepared to be flexible on:
Local working practices
Titles and structures, at least in the short term
Tools and processes where standardisation is not urgent
That balance reduces disruption while still moving towards a coherent organisation.
Governance and decision‑making for alliances and joint ventures
Traditional hierarchies often don’t work in co‑development or co‑commercialisation deals. Ambiguity over “who decides what” is a common source of friction and delay.
Design governance, don’t let it emerge
For each alliance or JV, define:
Strategic governance: Joint steering committees, frequency of meetings, scope of authority.
Operational governance: Who owns what across clinical, regulatory, manufacturing, safety, medical and commercial.
Decision rights:
Which decisions are unilateral (partner A or B can decide)?
Which are joint and require consensus?
What is the escalation path and timeline when there’s disagreement?
Put this into simple, usable decision‑rights matrices—not just legal agreements no one reads after signing.
Choose and support your “boundary leaders”
Alliance managers, programme leaders and function heads who operate across organisational lines need:
Clear mandates from their own executives
Skills in influencing, negotiation and conflict resolution
Air cover when they escalate issues rather than hiding them
HR and Talent should prioritise these roles in succession planning and leadership development; they are leverage points for partnership success.
Retaining and engaging critical talent during uncertainty
Uncertainty is inevitable; unmanaged, it drives your best people to the market.
Communicate honestly and rhythmically
Be clear about what you know and don’t know yet. Don’t over‑promise on roles and structures.
Set a communication cadence. For example, weekly updates in the first 6–8 weeks, then bi‑weekly or monthly.
Equip line managers. They’re the first line of engagement; give them FAQs, key messages and space to raise concerns.
Make the “new story” tangible
People stay when they can see a future for themselves:
Show how the combined or partnered organisation improves scientific impact, patient reach or career paths.
Highlight early integration wins (joint publications, aligned trials, new markets entered).
Involve critical talent in shaping how teams and processes will work.
Engagement comes from participation, not just information.
HR and Talent Acquisition: from support function to integration engine
HR and TA should position themselves as integration designers, not just implementers:
Workforce mapping: Understand who is where, doing what, on which critical programmes.
Risk assessment: Identify single‑points‑of‑failure and fragile teams.
Recruitment strategy: Anticipate where you will lose people and where new skills are needed for the combined strategy.
Leadership support: Provide coaching for leaders who are suddenly managing larger, more complex or cross‑company teams.
Done well, this elevates HR from “policy and process” to a central driver of deal success.
For 2027, forecasts point to continued strength in biotech and medtech M&A, but with more selective, targeted deals rather than a return to widespread mega-mergers.
Leadership integration after M&A or strategic partnerships is too important to leave to chance. If your organisation cannot clearly articulate how decisions are made across partners, who your critical talent are, and how you’re keeping them engaged, there is value—and risk—on the table.
Feel free to reach out to Sharon Shields Consulting if you would like to discuss.
References
McKinsey & Company — “Retain, integrate, thrive: A strategy for managing talent during M&A transactions”Useful for discussing the importance of identifying critical talent before deal announcement, maintaining communication during integration, and supporting employees after completion.https://www.mckinsey.com/capabilities/m-and-a/our-insights/retain-integrate-thrive-a-strategy-for-managing-talent-during-m-and-a-transactions
PwC — “People Integration in M&A”A practical reference covering leadership assessment, organisation design, employee retention, cultural integration, staffing and HR policy alignment.https://www.pwc.com/us/en/deals/mergers-acquisitions/assets/pwc-people-integration.pdf
Bain & Company — “Reimagining Talent in M&A”Helpful for explaining how organisations can assess attrition risk during due diligence, identify informal centres of influence and create a compelling post-deal vision.https://www.bain.com/insights/reimagining-talent-m-and-a-report-2022/
EY — “Value Creation from Bolt-On Life Sciences Acquisitions”Particularly relevant to your article because it focuses on life-sciences transactions, including people diligence, retention of key executives and employees, integration planning and governance.https://www.ey.com/en_us/insights/strategy/m-a-considerations-for-life-sciences-bolt-on-deals
Mintz / Mergermarket — “United Notions: Life Sciences M&A”A sector-specific report examining life-sciences M&A integration, employee retention, cultural fit and the use of dedicated integration teams.https://www.mintz.com/sites/default/files/media/documents/2021-06-10/Report-UNITED-NOTIONS_Mergermarket_Life_Sciences_M&A-2021-Mintz_0.PDF
McKinsey & Company — “Talent Retention and Selection in M&A”Useful for supporting points about targeted retention, manager communication, recognition and the selection of employees who are critical to the transition.https://www.mckinsey.de/~/media/McKinsey/Business%20Functions/M%20and%20A/Our%20insights/Talent%20retention%20and%20selection%20in%20M%20and%20A/Talent-retention-and-selection-in-M-and-A.pdf
Mercer — “Transforming M&A: How Technology and Human Insight Drive Deal Success”Relevant for the human-capital and rewards perspective, particularly the need to incorporate people considerations into the deal thesis and align incentives with integration objectives.https://www.mercer.com/en-us/insights/people-strategy/mergers-and-acquisitions/
PwC — “People at the Heart of Deals Success”Supports discussion of leadership integration, reward alignment, decision-making cultures, operating models and the link between talent retention planning and deal value.https://www.pwc.ch/en/insights/hr/people-in-deals.html
World Health Organization — Good Governance for MedicinesA useful governance reference for articles discussing ethics, transparency, accountability, risk management and decision-making in pharmaceutical partnerships and joint ventures.
OECD — G20/OECD Principles of Corporate GovernanceUseful for the board and governance sections, particularly responsibilities relating to oversight, accountability, risk and stakeholder interests.
International Council for Harmonisation — ICH E6 Good Clinical PracticeEssential if your article discusses clinical partnerships, investigators, sponsors, trial responsibilities, data integrity or governance of clinical programmes.
International Council for Harmonisation — ICH Q10 Pharmaceutical Quality SystemRelevant when discussing quality leadership, manufacturing partnerships, technology transfer, outsourced operations and maintaining quality oversight after an acquisition.
U.S. Food and Drug Administration — Contract Manufacturing Arrangements for Drugs: Quality AgreementsUseful for explaining how partners should clarify responsibilities for quality, manufacturing, change control, investigations and regulatory communication.
European Medicines Agency — Guideline on Good Pharmacovigilance PracticesRelevant to alliances and acquisitions involving safety reporting, pharmacovigilance responsibilities, signal management and oversight across organisations.
Center for Creative Leadership — Evidence-Driven Succession and Leadership Development ResearchUseful for supporting recommendations on leadership assessment, structured development, objective talent reviews and building a post-deal leadership pipeline.https://www.mckinsey.de/~/media/McKinsey/Business%20Functions/M%20and%20A/Our%20insights/Talent%20retention%20and%20selection%20in%20M%20and%20A/Talent-retention-and-selection-in-M-and-A.pdf



Comments